Most U.S. medical schools are earning high marks on an influential scorecard that grades their conflict-of-interest policies. In the latest edition of its PharmFree Scorecard, released April 9, the American Medical Student Assn. handed out A’s and B’s to 114, or 72%, of the nation’s 158 allopathic and osteopathic medical schools.
That represents a rise from last year’s results, which saw 102 schools, or 65%, get an A or a B. The scorecard grades schools’ policies on how tightly they restrict interactions with pharmaceutical companies, device makers and other medical industry firms in 11 areas such as gifts, meals, drug samples and faculty participation in speakers’ bureaus.
My latest. Read the whole shebang.